Novozymes A/S (VIE:NZYM)

Austria flag Austria · Delayed Price · Currency is EUR
52.18
-0.46 (-0.87%)
At close: Jun 22, 2026
Market Cap24.35B -16.6%
Revenue (ttm)4.20B +3.5%
Net Income596.70M +30.1%
EPS1.28 -19.1%
Shares Out n/a
PE Ratio40.81
Forward PE23.83
Dividend0.87 (1.65%)
Ex-Dividend DateMar 24, 2026
Volumen/a
Open52.36
Previous Close52.64
Day's Range52.18 - 52.42
52-Week Range45.31 - 63.90
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 20, 2026

About Novozymes

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; e... [Read more]

Industry Miscellaneous Chemical Products
Founded 1925
Employees 11,263
Stock Exchange Vienna Stock Exchange
Ticker Symbol NZYM

Financial Performance

In 2025, Novozymes's revenue was 4.16 billion, an increase of 8.45% compared to the previous year's 3.83 billion. Earnings were 583.60 million, an increase of 90.84%.

Financial Statements

News

Novonesis price target lowered to DKK 552 from DKK 560 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Novonesis (NVZMY) to DKK 552 from DKK 560 and keeps an Overweight rating on the shares.

27 days ago - TheFly

Novonesis upgraded to Buy from Hold at Kepler Cheuvreux

Kepler Cheuvreux analyst Patrick Roquas upgraded Novonesis (NVZMY) to Buy from Hold with a price target of DKK 460, up from DKK 390. The firm says the company has the…

5 weeks ago - TheFly

Novonesis price target raised to DKK 440 from DKK 415 at Citi

Citi raised the firm’s price target on Novonesis (NVZMY) to DKK 440 from DKK 415 and keeps a Buy rating on the shares.

6 weeks ago - TheFly

Novozymes Earnings Call Transcript: Q1 2026

Q1 2026 saw 7% organic sales growth, strong innovation, and margin resilience despite currency and input cost headwinds. Full-year guidance for 5%-7% organic growth and 37%-38% EBITDA margin is confirmed, with strategic investments supporting long-term targets.

7 weeks ago - Transcripts

Novozymes Quarterly report: Q1 2026

Novozymes has published its Q1 2026 quarterly earnings report on May 5, 2026.

7 weeks ago - Filings

Novozymes Slides: Q1 2026

Novozymes has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.

7 weeks ago - Filings

Novozymes Slides: Investor presentation

Novozymes has posted slides in relation to its latest quarterly earnings report, which was published on May 1, 2026.

7 weeks ago - Filings

Novonesis price target lowered to DKK 500 from DKK 540 at JPMorgan

JPMorgan lowered the firm’s price target on Novonesis (NVZMY) to DKK 500 from DKK 540 and keeps an Overweight rating on the shares.

2 months ago - TheFly

Novonesis upgraded to Buy from Neutral at Rothschild & Co Redburn

Rothschild & Co Redburn upgraded Novonesis (NVZMY) to Buy from Neutral with a DKK 445 price target

3 months ago - TheFly

Novonesis upgraded to Buy from Sell at Citi

Citi analyst Ranulf Orr upgraded Novonesis (NVZMY) to Buy from Sell with a DKK 415 price target The firm cites the stock’s valuation reset combined with the company’s “more resilient”…

3 months ago - TheFly

Novonesis price target lowered to DKK 410 from DKK 478 at Berenberg

Berenberg lowered the firm’s price target on Novonesis (NVZMY) to DKK 410 from DKK 478 and keeps a Buy rating on the shares.

3 months ago - TheFly

Novozymes Earnings Call Transcript: Q4 2025

Organic sales grew 7% in 2025, with strong volume-driven growth across all segments and a 37.1% adjusted EBITDA margin, despite currency headwinds. 2026 guidance targets 5%-7% organic growth and continued margin expansion, supported by innovation, synergies, and capacity investments.

4 months ago - Transcripts

Novozymes Annual report: Q4 2025

Novozymes has published its Q4 2025 annual report on February 25, 2026.

4 months ago - Filings

Novozymes Slides: Q4 2025

Novozymes has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.

4 months ago - Filings

Novonesis price target lowered to DKK 540 from DKK 560 at JPMorgan

JPMorgan analyst Chetan Udeshi lowered the firm’s price target on Novonesis (NVZMY) to DKK 540 from DKK 560 and keeps an Overweight rating on the shares.

4 months ago - TheFly

Novonesis price target raised to DKK 560 from DKK 512 at JPMorgan

JPMorgan analyst Chetan Udeshi raised the firm’s price target on Novonesis (NVZMY) to DKK 560 from DKK 512 and keeps an Overweight rating on the shares.

7 months ago - TheFly

Novonesis price target lowered to DKK 560 from DKK 569 at Morgan Stanley

Morgan Stanley analyst Thomas Wrigglesworth lowered the firm’s price target on Novonesis (NVZMY) to DKK 560 from DKK 569 and keeps an Overweight rating on the shares. Published first on…

7 months ago - TheFly

Novozymes Earnings Call Transcript: Q3 2025

Organic sales grew 8% in the first nine months, driven by strong volume growth, innovation, and emerging market performance. Adjusted EBITDA margin rose to 37.3% despite currency headwinds, and full-year guidance was raised to 7%-8% organic sales growth.

8 months ago - Transcripts

Novozymes Quarterly report: Q3 2025

Novozymes has published its Q3 2025 quarterly earnings report on November 6, 2025.

8 months ago - Filings

Novozymes Slides: Q3 2025

Novozymes has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.

8 months ago - Filings

Novonesis price target lowered to DKK 480 from DKK 490 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Novonesis (NVZMY) to DKK 480 from DKK 490 and keeps a Buy rating on the shares.

9 months ago - TheFly

Novonesis price target lowered to DKK 512 from DKK 545 at JPMorgan

JPMorgan lowered the firm’s price target on Novonesis (NVZMY) to DKK 512 from DKK 545 and keeps an Overweight rating on the shares.

10 months ago - TheFly

Novonesis price target lowered to DKK 490 from DKK 520 at Deutsche Bank

Deutsche Bank analyst Virginie Boucher-Ferte lowered the firm’s price target on Novonesis (NVZMY) to DKK 490 from DKK 520 and keeps a Buy rating on the shares. Published first on…

10 months ago - TheFly

Novonesis price target lowered to DKK 465 from DKK 530 at Berenberg

Berenberg lowered the firm’s price target on Novonesis (NVZMY) to DKK 465 from DKK 530 and keeps a Buy rating on the shares.

10 months ago - TheFly

Novonesis price target lowered to DKK 380 from DKK 400 at Citi

Citi analyst Ranulf Orr lowered the firm’s price target on Novonesis (NVZMY) to DKK 380 from DKK 400 and keeps a Sell rating on the shares.

10 months ago - TheFly